PL3723858T3 - Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim - Google Patents
Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkimInfo
- Publication number
- PL3723858T3 PL3723858T3 PL19836806T PL19836806T PL3723858T3 PL 3723858 T3 PL3723858 T3 PL 3723858T3 PL 19836806 T PL19836806 T PL 19836806T PL 19836806 T PL19836806 T PL 19836806T PL 3723858 T3 PL3723858 T3 PL 3723858T3
- Authority
- PL
- Poland
- Prior art keywords
- fixaxfx
- light chain
- bispecific antibody
- common light
- common
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820977.5A GB201820977D0 (en) | 2018-12-21 | 2018-12-21 | Fixaxfx bispecific antibody with commomn light chain |
| GBGB1906816.2A GB201906816D0 (en) | 2019-05-15 | 2019-05-15 | FIXaxFX bispecific antibody with common light chain |
| GBGB1908190.0A GB201908190D0 (en) | 2019-06-07 | 2019-06-07 | Fixaxfx bispecific antibody with common light chain |
| PCT/EP2019/086808 WO2020128049A1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
| EP19836806.0A EP3723858B1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3723858T3 true PL3723858T3 (pl) | 2022-03-07 |
Family
ID=69167786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19836806T PL3723858T3 (pl) | 2018-12-21 | 2019-12-20 | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10815308B2 (https=) |
| EP (2) | EP3723858B1 (https=) |
| JP (1) | JP7530362B2 (https=) |
| KR (1) | KR20210118085A (https=) |
| CN (1) | CN113453757B (https=) |
| BR (1) | BR112021012065A2 (https=) |
| CA (1) | CA3123177A1 (https=) |
| DK (1) | DK3723858T3 (https=) |
| ES (1) | ES2901683T3 (https=) |
| HR (1) | HRP20220088T1 (https=) |
| HU (1) | HUE057634T2 (https=) |
| LT (1) | LT3723858T (https=) |
| PL (1) | PL3723858T3 (https=) |
| PT (1) | PT3723858T (https=) |
| RS (1) | RS62848B1 (https=) |
| SI (1) | SI3723858T1 (https=) |
| TW (1) | TWI772724B (https=) |
| WO (1) | WO2020128049A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| PL3723858T3 (pl) * | 2018-12-21 | 2022-03-07 | Kymab Limited | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
| GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| US20230250192A1 (en) * | 2019-05-15 | 2023-08-10 | Kymab Limited | Improved lambda antibodies |
| CN115728433B (zh) * | 2021-08-27 | 2024-11-15 | 联邦生物科技(珠海横琴)有限公司 | IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| WO2023147574A2 (en) * | 2022-01-31 | 2023-08-03 | The Children's Hospital Of Philadelphia | Compositions and methods for treating factor ix deficiency |
| AR129879A1 (es) * | 2022-07-08 | 2024-10-09 | Novo Nordisk As | Compuestos de isvd altamente potentes capaces de sustituir al fviii(a) |
| GB202319967D0 (en) | 2023-12-22 | 2024-02-07 | Epsilogen Ltd | Heteromultimeric proteins |
| WO2026036047A1 (en) * | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
| WO2026037918A1 (en) | 2024-08-14 | 2026-02-19 | Epsilogen Ltd | Heteromultimeric proteins |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2005035754A1 (ja) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CA2603264C (en) | 2005-04-08 | 2017-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| KR20080030960A (ko) | 2005-07-05 | 2008-04-07 | 글락소 그룹 리미티드 | Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도 |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| US20080102065A1 (en) * | 2006-04-14 | 2008-05-01 | Borges Luis G | Erythropoietin receptor extended duration limited agonists |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| KR101856792B1 (ko) * | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| EP2906599B1 (en) | 2012-10-12 | 2019-07-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| RU2687043C2 (ru) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN105848668A (zh) | 2013-11-04 | 2016-08-10 | 加利福尼亚大学董事会 | 治疗或预防与出血或低凝血相关联的病状的疗法 |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| CA2978038A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| EP3313871A1 (en) * | 2015-06-26 | 2018-05-02 | Institute for Research in Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| JP6920293B2 (ja) | 2015-10-30 | 2021-08-18 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ＩｇＧ軽鎖におけるＮ末端切断の防止 |
| US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| RU2767329C2 (ru) | 2016-02-06 | 2022-03-17 | Эпимаб Биотерапьютикс, Инк. | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
| CN109563154B (zh) | 2016-05-16 | 2024-12-13 | 武田药品工业株式会社 | 抗帕多瓦因子ix抗体 |
| KR102591955B1 (ko) * | 2016-07-29 | 2023-10-19 | 추가이 세이야쿠 가부시키가이샤 | 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체 |
| RU2766233C2 (ru) | 2016-09-06 | 2022-02-10 | Чугаи Сейяку Кабусики Кайся | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x |
| US20230192896A1 (en) * | 2016-11-23 | 2023-06-22 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| EP3577140A1 (en) | 2017-02-01 | 2019-12-11 | Novo Nordisk A/S | Procoagulant antibodies |
| US20210284715A1 (en) | 2017-02-06 | 2021-09-16 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| IL270138B2 (en) * | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| EP3621643A4 (en) | 2017-05-11 | 2021-07-21 | Atreca, Inc. | ANTIBODY ANTI-MALARIA BOUND WITH CIRCUMSPOROZOID PROTEIN |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| AR113142A1 (es) | 2017-09-29 | 2020-01-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo |
| US11787874B2 (en) | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
| PL3723858T3 (pl) * | 2018-12-21 | 2022-03-07 | Kymab Limited | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
-
2019
- 2019-12-20 PL PL19836806T patent/PL3723858T3/pl unknown
- 2019-12-20 PT PT198368060T patent/PT3723858T/pt unknown
- 2019-12-20 US US16/722,452 patent/US10815308B2/en active Active
- 2019-12-20 HU HUE19836806A patent/HUE057634T2/hu unknown
- 2019-12-20 EP EP19836806.0A patent/EP3723858B1/en active Active
- 2019-12-20 WO PCT/EP2019/086808 patent/WO2020128049A1/en not_active Ceased
- 2019-12-20 HR HRP20220088TT patent/HRP20220088T1/hr unknown
- 2019-12-20 US US17/311,595 patent/US20220064327A1/en not_active Abandoned
- 2019-12-20 LT LTEPPCT/EP2019/086808T patent/LT3723858T/lt unknown
- 2019-12-20 SI SI201930150T patent/SI3723858T1/sl unknown
- 2019-12-20 BR BR112021012065A patent/BR112021012065A2/pt not_active Application Discontinuation
- 2019-12-20 ES ES19836806T patent/ES2901683T3/es active Active
- 2019-12-20 DK DK19836806.0T patent/DK3723858T3/da active
- 2019-12-20 KR KR1020217022770A patent/KR20210118085A/ko not_active Ceased
- 2019-12-20 CA CA3123177A patent/CA3123177A1/en active Pending
- 2019-12-20 TW TW108146911A patent/TWI772724B/zh active
- 2019-12-20 CN CN201980091786.3A patent/CN113453757B/zh active Active
- 2019-12-20 EP EP21204339.2A patent/EP4015538A1/en active Pending
- 2019-12-20 RS RS20220069A patent/RS62848B1/sr unknown
- 2019-12-20 JP JP2021535950A patent/JP7530362B2/ja active Active
-
2020
- 2020-10-06 US US17/063,905 patent/US11976135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11976135B2 (en) | 2024-05-07 |
| US20220064327A1 (en) | 2022-03-03 |
| US20200199250A1 (en) | 2020-06-25 |
| LT3723858T (lt) | 2022-02-10 |
| US10815308B2 (en) | 2020-10-27 |
| ES2901683T3 (es) | 2022-03-23 |
| RS62848B1 (sr) | 2022-02-28 |
| SI3723858T1 (sl) | 2022-04-29 |
| BR112021012065A2 (pt) | 2021-12-07 |
| CN113453757A (zh) | 2021-09-28 |
| CA3123177A1 (en) | 2020-06-25 |
| TWI772724B (zh) | 2022-08-01 |
| JP7530362B2 (ja) | 2024-08-07 |
| EP3723858A1 (en) | 2020-10-21 |
| EP3723858B1 (en) | 2021-10-27 |
| WO2020128049A1 (en) | 2020-06-25 |
| PT3723858T (pt) | 2022-02-02 |
| HRP20220088T1 (hr) | 2022-04-15 |
| TW202039584A (zh) | 2020-11-01 |
| US20210101997A1 (en) | 2021-04-08 |
| HUE057634T2 (hu) | 2022-05-28 |
| CN113453757B (zh) | 2024-06-28 |
| DK3723858T3 (da) | 2022-01-24 |
| EP4015538A1 (en) | 2022-06-22 |
| KR20210118085A (ko) | 2021-09-29 |
| JP2022515770A (ja) | 2022-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3723858T (pt) | Anticorpo biespecífico fixaxfx com cadeia leve comum | |
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| EP3243840B8 (en) | Bispecific antibody or antibody mixture with common light chains | |
| IL279321A (en) | Anti-SIRPalpha antibody | |
| IL283812A (en) | Humanized antibody against human pd–1 | |
| ZA202004908B (en) | Bispecific antibody | |
| EP3941944A4 (en) | Claudin-6 bispecific antibodies | |
| SG11202004172UA (en) | Il2rbeta/common gamma chain antibodies | |
| GB201817172D0 (en) | Antibody | |
| CA187451S (en) | Light | |
| CA185679S (en) | Light | |
| IL253579A0 (en) | Anti-light chain substituent antibodies | |
| CA187452S (en) | Light | |
| IL289252A (en) | Ep2 antagonist | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| CA187450S (en) | Light | |
| IL286757A (en) | Antibodies in specific | |
| GB201811368D0 (en) | Antibody | |
| IL286918A (en) | Bispecific antibody | |
| IL290050A (en) | Bispecific antibody | |
| SG10202006332PA (en) | Transgenic rabbit with common light chain | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| PL3763993T3 (pl) | Światło samochodowe | |
| GB201820977D0 (en) | Fixaxfx bispecific antibody with commomn light chain | |
| GB201908190D0 (en) | Fixaxfx bispecific antibody with common light chain |